This article is more than 5 years old. Information may no longer be current.
MEN1 associated with early-onset breast cancer risk in women
Click Here to Manage Email Alerts
Women with multiple endocrine neoplasia type 1 are at greater risk for developing early-onset breast cancer compared with women without the disease, according to findings from a cross-sectional study.
Rachel S. van Leeuwaarde, MD, of the department of endocrine oncology at University Medical Center Utrecht, the Netherlands, and colleagues analyzed data from 138 women with confirmed multiple endocrine neoplasia type 1 (MEN1) or a MEN1 mutation from the Dutch MEN1 cohort, a longitudinal database that includes at least 90% of all Dutch MEN1 patients aged at least 16 years. Women completed either a written or online questionnaire between April 2015 and October 2016 regarding breast cancer-related endocrine risk factors, cancer family history and other known risk factors for breast cancer. Researchers compared the age at breast cancer diagnosis among the MEN1 cohort with the female relatives without MEN1, as well as age of breast cancer onset in the general Dutch population using data from the Netherlands Cancer Registry.
Respondents were from 64 families, with a median of two respondents per family. Within the cohort, 11 women had breast cancer and MEN1; researchers also identified 34 relatives with breast cancer in the families of responders (11 relatives were obligate MEN1 carriers; 14 had no MEN1 mutation; nine had unknown MEN1 status).
The median age at breast cancer diagnosis for women with MEN1 (n = 22) was age 45 years vs. age 58 years in women without MEN1 (n = 14; P = .03) and age 61 years in the Dutch reference population (2009-2013).
Researchers also found that five of 35 women with MEN1 having a negative MEN1 mutation test had breast cancer, resembling the odds of breast cancer for women from the reference population; the median age of breast cancer in those patients was 60 years.
Researchers did not observe between-group differences for known endocrine risk factors, including age at menarche, oral contraception use, pregnancy, age at first birth, parity and breast-feeding; there were no between-group differences for smoking status and alcohol consumption.
Van Leeuwaarde wrote that biennial breast cancer surveillance from age 40 years for all women with the MEN1 should be considered for daily clinical practice.
“Physicians should be aware of early breast cancer onset in females with MEN1 and should consider breast cancer screening from age 40 years,” van Leeuwaarde told Endocrine Today. “An international case-control study to assess endocrine and general risk factors for breast cancer occurrence in women with MEN1 will provide further insight in a larger MEN1 cohort.” – by Regina Schaffer
For more information:
Rachel S. van Leeuwaarde, MD, can be reached at the Department of Endocrine Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, Netherlands; email: R.vanLeeuwaarde@umcutrecht.nl.
Disclosure: van Leeuwaarde reports receiving an unrestricted grant from Ipsen.
Click Here to Manage Email Alerts